Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltanexor and Venetoclax in Relapsed or Refractory MDS and AML
NCT06399640Phase 1Recruiting
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Aug 2024
- Primary completion
- Feb 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of eltanexor in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), sponsored by Vanderbilt-Ingram Cancer Center. Primary endpoints: Incidence of adverse events up to 2 years and Biologically effective dose up to 2 years. Started Aug 2024; status: recruiting.
02
Drugs
eltanexor
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06399640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06399640.